Clinical Trials on Gray+Platelet+Syndrome

Total 39527 results

Aarhus University Hospital
University of Aarhus

Completed

Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients

Extracorporeal Membrane Oxygenation | Platelet Aggregation | Platelet Activation | Intensive Care Units | Blood Platelets | Platelet Function Tests

Denmark
Centre Hospitalier Universitaire, Amiens

Recruiting

Characterization and Quantification of Platelet/Leukocyte Aggregates in Patients With Suspected Heparin-induced Thrombocytopenia (HITSTREAM)

Heparin-induced Thrombocytopenia | Platelet Activation | Platelets | Leukocytes | HIT | Platelet/Leukocyte Aggregates | HITSTREAM | Flow Cytometry

France
National Human Genome Research Institute (NHGRI)

Completed

Genetic Analysis of Gray Platelet Syndrome

Myelofibrosis | Genetic Linkage

United States
University Hospital Muenster
Study Chair and Principal Investigator: Univ.-Prof. Dr. Alexander Zarbock; Principal...

Recruiting

PLAIAR-Trial: Platelets in Inflammation and Resolution (PLAIAR)

ARDS | Platelet Abnormality

Germany
Peter MacCallum Cancer Centre, Australia
National Health and Medical Research Council, Australia; University of Melbourne

Recruiting

Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) (IBMDx)

Hematologic Diseases | Inherited Platelet Disorder | Inherited BMF Syndrome

Australia
Hikari Dx, Inc.
Fujimori Kogyo Co., Ltd.

Completed

Clinical Performance Evaluation of T-TAS 01 PL Chip

Healthy | Von Willebrand Diseases | Platelet Dysfunction | Congenital Platelets Abnormality

United States, France
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Terminated

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

Thrombocytopenia | Myelodysplastic Syndrome (MDS)

United States
Tarix Pharmaceuticals

Terminated

Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

Myelodysplastic Syndrome (MDS)

United States
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
Gesellschaft fur Medizinische Innovation - Hamatologie...
Amgen

Completed

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (EUROPE)

Myelodysplastic Syndromes

France, Germany
Associazione Qol-one

Active, not recruiting

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Thrombocytopenia

France, Germany, Italy, Slovenia
Nordic MDS Group
GlaxoSmithKline

Completed

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS) (NMDSG10A)

Thrombocytopenia | Myelodysplastic Syndrome

Sweden
Amgen

Completed

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Myelodysplastic Syndromes | Thrombocytopenia
Amgen

Completed

Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS
Amgen

Completed

Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Myelodysplastic Syndromes | Thrombocytopenia | MDS
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
National Cancer Institute (NCI)

Recruiting

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid Malignancies

United States
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Thrombocytopenia

United States
Tongji Hospital

Not yet recruiting

Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.

Myelodysplastic Syndromes
Cellphire Therapeutics, Inc.
Department of Health and Human Services

Terminated

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Myelodysplastic Syndromes | Myeloproliferative Disorders | Thrombocytopenia | Hematologic Malignancy | Bone Marrow Aplasia | Platelet Refractoriness

United States, Israel, Norway
Washington University School of Medicine

Recruiting

Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Clonal Cytopenia of Undetermined Significance

United States
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
HOSPITAL BRITANICO DE BUENOS AIRES

Recruiting

STUDY OF SURVIVAL AND FUNCTIONALITY IN CRYOPRESERVED PLATELETS

Platelet Cryopreservation | Platelet Survival

Argentina
Centre Hospitalier Universitaire, Amiens

Recruiting

PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer (PLATELETSTREAM)

Platelet Aggregation | Heparin-induced Thrombocytopenia | Platelet Activation | Platelet Disorder

France
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Myelodysplastic Syndromes | Leukemia | Congenital Amegakaryocytic Thrombocytopenia | Severe Congenital Neutropenia

United States
The First Affiliated Hospital of Soochow University

Recruiting

Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

Platelet Disorder

China
University Hospital, Bordeaux

Completed

Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 (SHU O104 CUB)

Escherichia Coli Infections | Hemolytic-uremic Syndrome

France
GlaxoSmithKline

Completed

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Myelodysplastic Syndrome

Puerto Rico, United States, Taiwan, Germany, Denmark, Hong Kong, Korea, Republic of, France, United Kingdom, Italy, Brazil
University Hospital, Geneva

Completed

Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

Acquired Platelet Disorder

Switzerland
Ayman Saad
Sobi, Inc.

Withdrawn

Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant

Platelet Disorder
Jane Liesveld

Completed

Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

Thrombocytopenia | Acute Radiation Syndrome
Region Stockholm
Karolinska Institutet

Recruiting

Towards Improved Diagnostics for Suspected Platelet Function Disorders

Platelet Disorder | Thrombocytopathy | Platelet Function Disorder

Sweden
M.D. Anderson Cancer Center

Not yet recruiting

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet Disorder | Hematopoietic

United States
IRCCS Policlinico S. Matteo

Completed

Eltrombopag for Inherited Thrombocytopenias

Inherited Platelet Disorder

Italy
Institut National de la Santé Et de la Recherche...

Enrolling by invitation

Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) (CATCH)

Thrombocytopenia | Inherited Platelet Disorder

France
University of Calgary

Withdrawn

Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion

Hemolytic-Uremic Syndrome

Canada
Anjali Sharathkumar
Amgen

Active, not recruiting

TPO-Mimetic Use in Children for Hematopoietic Failure

Thrombocytopenia | Bone Marrow Failure Disorders | Aplastic Anemia | Refractory Cytopenia of Childhood | Myelodysplastic Syndrome(MDS)

United States
Beth Israel Deaconess Medical Center
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry

Healthy | Platelet Activation Testing Before/After Anti-platelet Therapy

United States
Drexel University College of Medicine

Completed

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Thrombocytopenia

United States
Aggredyne, Inc.

Completed

AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction

Platelet Dysfunction Due to Aspirin Ingestion

United States
Gyeongsang National University Hospital

Completed

Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome

Bleeding | Acute Coronary Syndrome | Platelet Thrombus

Korea, Republic of
Institute of Hematology & Blood Diseases Hospital

Recruiting

Anti-CD38 Antibody Treating APS With Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome

China
Malaysia Palm Oil Board
Universiti Putra Malaysia

Completed

Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome

Metabolic Syndrome | Platelet Aggregation, Spontaneous

Malaysia
Aggredyne, Inc.

Completed

Study of AggreGuide A-100 (ADP) Assay

Risk Factor, Cardiovascular | Platelet Dysfunction Due to Drugs
Zhang Lei, MD

Recruiting

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome | Treatment

China
The First Affiliated Hospital of Dalian Medical...

Completed

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Percutaneous Coronary Intervention | Aged | Platelet Aggregation Inhibitors | Dual Anti-Platelet Therapy

China
Etablissement Français du Sang
University of Marseille

Completed

Platelet Dysfunction in Blood Donors (DysPlaq)

Platelet Dysfunction in Blood Donors

France
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Anti-CD38 Antibody Treating Evans Syndrome (2023-D-ES)

Treatment | Evan Syndrome

China

Clinical Trials on Gray+Platelet+Syndrome

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations